| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
KX-01-191 is a tin reagent precursor and does not have a defined biological target. The compound contains a tributylstannyl group, which is a common organotin moiety used in Stille coupling reactions for the formation of carbon-carbon bonds in organic synthesis. It serves as a synthetic intermediate rather than a pharmacologically active agent.
|
|---|---|
| ln Vitro |
KX-01-191 does not have direct in vitro biological activity as it is a synthetic intermediate. The compound is used as a precursor in chemical synthesis to prepare other compounds that may have biological activity. Its role is in medicinal chemistry and drug discovery as a building block for the synthesis of potential therapeutic agents.
|
| ln Vivo |
KX-01-191 does not have direct in vivo biological activity as it is a synthetic intermediate. The compound is used in chemical synthesis to prepare other compounds that may be evaluated in preclinical models. Its role is in medicinal chemistry as a building block for drug discovery.
|
| Enzyme Assay |
KX-01-191 is a chemical reagent used in synthetic chemistry. Its properties are characterized by standard chemical analysis methods, including NMR spectroscopy, mass spectrometry, and HPLC. The compound is used as a precursor in Stille coupling reactions for the synthesis of complex organic molecules.
|
| Cell Assay |
KX-01-191 does not have direct cellular activity. It is used in chemical synthesis to prepare other compounds that may be evaluated in cellular assays. Its role is in medicinal chemistry as a synthetic intermediate for the preparation of potential therapeutic agents.
|
| Animal Protocol |
KX-01-191 does not have direct in vivo activity. It is used in chemical synthesis to prepare other compounds that may be evaluated in animal models. Its role is in medicinal chemistry as a building block for drug discovery.
|
| ADME/Pharmacokinetics |
KX-01-191 (molecular weight 552.34, formula C₂₈H₃₉N₃OSn) is a small-molecule compound containing a tin atom. It is a solid and is typically stored at -20°C. The compound is soluble in DMSO and is used as a chemical reagent in organic synthesis.
|
| Toxicity/Toxicokinetics |
KX-01-191 is a chemical reagent and does not have a defined toxicity profile as a drug. Appropriate safety precautions should be taken when handling organotin compounds, as they can be toxic.
|
| References | |
| Additional Infomation |
KX-01-191 (compound 5c′) is a tin reagent precursor used in chemical synthesis. It contains a tributylstannyl group and is used as a synthetic intermediate for Stille coupling reactions. The compound is not a drug and does not have direct biological activity. It is used in medicinal chemistry research for the synthesis of potential therapeutic agents.
|
| Molecular Formula |
C28H39N3OSN
|
|---|---|
| Molecular Weight |
552.338766336441
|
| Exact Mass |
553.211
|
| CAS # |
2211903-84-1
|
| PubChem CID |
138911352
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
33
|
| Complexity |
599
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCC[Sn](CCCC)(CCCC)C1=CC=C(C=C1)C2=NC3=CC=CC4=C3N2CCNC4=O
|
| InChi Key |
AOQSHPQTNVDAAF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12N3O.3C4H9.Sn/c20-16-12-7-4-8-13-14(12)19(10-9-17-16)15(18-13)11-5-2-1-3-6-11;3*1-3-4-2;/h2-8H,9-10H2,(H,17,20);3*1,3-4H2,2H3;
|
| Chemical Name |
2-(4-tributylstannylphenyl)-1,3,10-triazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-9-one
|
| Synonyms |
KX-01-191; KX 01-191; KX-01 191
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~181.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8105 mL | 9.0524 mL | 18.1048 mL | |
| 5 mM | 0.3621 mL | 1.8105 mL | 3.6210 mL | |
| 10 mM | 0.1810 mL | 0.9052 mL | 1.8105 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA